Cargando…

SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments

For three years, the novel coronavirus disease 2019 (COVID-19) pandemic, caused by infection of the SARS-CoV-2 virus, has completely changed our lifestyles and prepared us to live with this novel pneumonia for years to come. Given that pre-existing flu is caused by the influenza A virus, we have beg...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinyi, Li, Jingwen, Liu, Hanshu, Hu, Xinyu, Lin, Zhicheng, Xiong, Nian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051779/
https://www.ncbi.nlm.nih.gov/pubmed/36985154
http://dx.doi.org/10.3390/microorganisms11030580
_version_ 1785014971858419712
author Wang, Xinyi
Li, Jingwen
Liu, Hanshu
Hu, Xinyu
Lin, Zhicheng
Xiong, Nian
author_facet Wang, Xinyi
Li, Jingwen
Liu, Hanshu
Hu, Xinyu
Lin, Zhicheng
Xiong, Nian
author_sort Wang, Xinyi
collection PubMed
description For three years, the novel coronavirus disease 2019 (COVID-19) pandemic, caused by infection of the SARS-CoV-2 virus, has completely changed our lifestyles and prepared us to live with this novel pneumonia for years to come. Given that pre-existing flu is caused by the influenza A virus, we have begun unprecedently co-coping with two different respiratory diseases at the same time. Hence, we draw a comparison between SARS-CoV-2 and influenza A virus based on the general characteristics, especially the main variants’ history and the distribution of the two viruses. SARS-CoV-2 appeared to mutate more frequently and independently of locations than the influenza A virus. Furthermore, we reviewed present clinical trials on combined management against COVID-19 and influenza in order to explore better solutions against both at the same time.
format Online
Article
Text
id pubmed-10051779
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100517792023-03-30 SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments Wang, Xinyi Li, Jingwen Liu, Hanshu Hu, Xinyu Lin, Zhicheng Xiong, Nian Microorganisms Review For three years, the novel coronavirus disease 2019 (COVID-19) pandemic, caused by infection of the SARS-CoV-2 virus, has completely changed our lifestyles and prepared us to live with this novel pneumonia for years to come. Given that pre-existing flu is caused by the influenza A virus, we have begun unprecedently co-coping with two different respiratory diseases at the same time. Hence, we draw a comparison between SARS-CoV-2 and influenza A virus based on the general characteristics, especially the main variants’ history and the distribution of the two viruses. SARS-CoV-2 appeared to mutate more frequently and independently of locations than the influenza A virus. Furthermore, we reviewed present clinical trials on combined management against COVID-19 and influenza in order to explore better solutions against both at the same time. MDPI 2023-02-24 /pmc/articles/PMC10051779/ /pubmed/36985154 http://dx.doi.org/10.3390/microorganisms11030580 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wang, Xinyi
Li, Jingwen
Liu, Hanshu
Hu, Xinyu
Lin, Zhicheng
Xiong, Nian
SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments
title SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments
title_full SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments
title_fullStr SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments
title_full_unstemmed SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments
title_short SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments
title_sort sars-cov-2 versus influenza a virus: characteristics and co-treatments
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051779/
https://www.ncbi.nlm.nih.gov/pubmed/36985154
http://dx.doi.org/10.3390/microorganisms11030580
work_keys_str_mv AT wangxinyi sarscov2versusinfluenzaaviruscharacteristicsandcotreatments
AT lijingwen sarscov2versusinfluenzaaviruscharacteristicsandcotreatments
AT liuhanshu sarscov2versusinfluenzaaviruscharacteristicsandcotreatments
AT huxinyu sarscov2versusinfluenzaaviruscharacteristicsandcotreatments
AT linzhicheng sarscov2versusinfluenzaaviruscharacteristicsandcotreatments
AT xiongnian sarscov2versusinfluenzaaviruscharacteristicsandcotreatments